Supplies Still Limited More Than a Year After Monoclonal Antibodies Authorized for Treating COVID-19

Dr. Aldo Calvo, Medical Director of Family Medicine at Broward Health, shows a Regeneron monoclonal antibody infusion bag during a news conference at the Hospital in Fort Lauderdale, Fla., on Aug. 19, 2021. Joe Cavaretta/South Florida Sun-Sentinel via AP

Despite being the only authorized outpatient medical therapy for preventing the worsening of COVID-19 symptoms in high-risk patients, there remains no steady supply of monoclonal antibodies from the federal government a year after its approval for use by medical regulators.

Rolled out in the same month as the COVID-19 vaccines, monoclonal antibody therapies have not gotten the attention that vaccine treatments have after they were billed as the thing to get America out of the pandemic.